Recurrence patterns following neoadjuvant chemotherapy combined with immunotherapy for esophageal squamous cell carcinoma
Diseases of the Esophagus · 03.05.2025 · 38 (3)
DOI: 10.1093/dote/doaf034 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diseases of the Esophagus, online erschienen am 19.05.2025. Verfasst von Miao Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, China. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Neoadjuvant Therapy, Esophageal Squamous Cell Carcinoma, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
This study aims to examine the recurrence patterns in patients with locally advanced esophageal squamous cell carcinoma who underwent surgery following neoadjuvant chemotherapy combined with immunotherapy. Retrospective analysis of patients with esophageal squamous cell carcinoma who received neoadjuvant Chemo-IO before surgery at Zhejiang Cancer Hospital between 2019 and 2023. The clinicopathological features, recurrence patterns, overall survival (OS), and disease-free survival (DFS) were analyzed, and the impact of postoperative adjuvant radiotherapy on prognosis was evaluated. In total, 422 patients were included in the study. After a median follow-up of 22 months, disease recurrence was observed in 89 (21.1%) patients, comprising 37 cases (8.8%) of locoregional recurrence, 30 cases (7.1%) of distant metastasis, and 22 cases (5.2%) of combined recurrence. Patients who achieved a pathologic complete response demonstrated significantly higher 3-year OS rates (90.0% vs. 72.5%; P = 0.01) and DFS rates (73.2% vs. 61.8%; P = 0.046). Univariable and multivariable analyses identified pathological lymph node staging (ypN0 vs. ypN+; HR: 1.73; 95% CI: 1.01–2.99; P = 0.047) as an independent prognostic factor for locoregional recurrence. Kaplan–Meier curves for OS and DFS demonstrated that postoperative radiotherapy (PORT) significantly improved OS and DFS in ypN+ patients after propensity score matching. Additionally, PORT significantly enhanced locoregional recurrence-free survival and distant recurrence-free survival in ypN+ patients. In patients receiving neoadjuvant Chemo-IO, locoregional recurrence is the predominant recurrence pattern. For ypN+ patients, PORT significantly improved survival outcomes. However, long-term outcomes require further investigation through randomized controlled trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
- Melbourne Medical School, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, VIC, Australia.
- Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou, China.
Zitieren
APA
Wang, M., Wang, X., Liu, Z., Shen, H., Qi, B., Fang, M., Wang, J., Ji, Y., & Zeng, J. (2025). Recurrence patterns following neoadjuvant chemotherapy combined with immunotherapy for esophageal squamous cell carcinoma. Diseases of the Esophagus, 38(3). https://doi.org/10.1093/dote/doaf034
Vancouver
Wang M, Wang X, Liu Z, Shen H, Qi B, Fang M, et al. Recurrence patterns following neoadjuvant chemotherapy combined with immunotherapy for esophageal squamous cell carcinoma. Diseases of the Esophagus. 2025;38(3). doi:10.1093/dote/doaf034
BibTeX
@article{Wang2025,
author = {Wang, Miao and Wang, Xinyi and Liu, Zhourong and Shen, Haixia and Qi, Baojia and Fang, Min and Wang, Jin and Ji, Yongling and Zeng, Jian},
title = {Recurrence patterns following neoadjuvant chemotherapy combined with immunotherapy for esophageal squamous cell carcinoma},
journal = {Diseases of the Esophagus},
year = {2025},
volume = {38},
number = {3},
doi = {10.1093/dote/doaf034}
}
EUVIMED